MCID: GLC008
MIFTS: 42

Glucose Metabolism Disease malady

Categories: Metabolic diseases

Aliases & Classifications for Glucose Metabolism Disease

Aliases & Descriptions for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 14
Glucose Metabolism Disorders 42 69
Disorder of Glucose Metabolism 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4194
MeSH 42 D044882
NCIt 47 C53655
SNOMED-CT 64 126877002
UMLS 69 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus, insulin-dependent and hemolytic anemia due to triosephosphate isomerase deficiency. An important gene associated with Glucose Metabolism Disease is INS (Insulin), and among its related pathways/superpathways are Developmental Biology and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Pancrelipase and Zinc have been mentioned in the context of this disorder. Related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Related Disease Score Top Affiliating Genes
1 diabetes mellitus, insulin-dependent 10.8
2 hemolytic anemia due to triosephosphate isomerase deficiency 10.8
3 cataract 10.5 ALB CRP INS
4 submucous uterine fibroid 10.4 ALB HBA2 INS
5 listeriosis 10.4 ACE ADIPOQ REN
6 hypersensitivity syndrome, carbamazepine-induced 10.4 ALB HBA2 INS
7 congenital nystagmus 10.4 ACE ALB REN
8 agammaglobulinemia 6 10.4 ACE ALB INS
9 prostate neuroendocrine neoplasm 10.4 ACE ALB REN
10 brain angioma 10.4 IGF1 IRS1
11 hyperphosphatemia 10.4 INS LEP PPARG
12 hypotrichosis simplex 10.4 ACE REN
13 hyperinsulinemic hypoglycemia, familial, 5 10.4 IGF1 INS IRS1
14 leg dermatosis 10.4 ADIPOQ INS LEP
15 myopia 10.4 ACE ALB REN
16 acute infection of pinna 10.4 CRP INS
17 tmem231-related joubert syndrome 10.4 HBA2 IGF1 INS
18 autosomal recessive congenital ichthyosis 10.4 INS LEP PPARG SLC2A4
19 hemopericardium 10.4 ALB HBA2 INS
20 iida kannari syndrome 10.4 ACE ADIPOQ INS PPARG
21 not otherwise specified 3-mga-uria type 10.4 ADIPOQ INS LEP
22 autoimmune disease 1 10.4 CRP GCG INS
23 mosaic trisomy 13 10.4 GCK IAPP INS
24 peripheral degeneration of cornea 10.4 GCG GIP INS
25 acquired angioedema 10.4 ADIPOQ PPARG
26 petrositis 10.4 ACE ALB REN
27 citrullinemia, type ii, neonatal-onset 10.4 ACE ALB IGF1 INS
28 bladder sarcoma 10.4 ALB IGF1 LEP
29 central nervous system leiomyoma 10.4 ALB CRP IGF1 LEP
30 thymus clear cell carcinoma 10.4 ADIPOQ INS LEP PPARG
31 schizotypal personality disorder 10.4 ACE ALB CRP REN
32 microphthalmia, syndromic 8 10.4 GCG INS
33 epidural spinal canal meningioma 10.4 IGF1 INS LEP
34 malignant hyperthermia susceptibility 1 10.4 ACE ALB APOB
35 ischemic optic neuropathy 10.4 ACE ALB CRP
36 joint disorders 10.4 ACE APOB CRP INS
37 cetp-related hyperalphalipoproteinemia 10.4 ACE APOB INS PPARG
38 brucella canis brucellosis 10.4 HBA2 IGF1 INS
39 choroiditis 10.4 ACE ALB CRP
40 fetal warfarin syndrome 10.4 APOB IGF1 INS LEP
41 exophthalmic ophthalmoplegia 10.4 ADIPOQ ALB LEP
42 acrocephalopolydactyly 10.4 ADIPOQ LEP
43 posterior uveal melanoma 10.4 ADIPOQ APOB CRP INS
44 maturity-onset diabetes of the young, type 13 10.4 GCG GCK INS
45 meningitis 10.4 ADIPOQ INS IRS1 LEP
46 congenital chloride diarrhea 10.4 ACE ALB APOB CRP
47 edict syndrome 10.4 IGF1 INS IRS1 LEP
48 primary biliary cirrhosis 10.4 IGF1 INS IRS1 LEP
49 deafness, autosomal recessive 79 10.4 ACE CRP REN
50 focal dystonia 10.4 ACE APOB CRP

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

MGI Mouse Phenotypes related to Glucose Metabolism Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 GCK GIP IAPP IGF1 INS IRS1
2 growth/size/body region MP:0005378 10.28 ACE ADIPOQ APOB DPP4 GCK GIP
3 cardiovascular system MP:0005385 10.2 LEP PPARG REN SLC2A4 ACE ADIPOQ
4 endocrine/exocrine gland MP:0005379 10.17 ACE ADIPOQ ALB DPP4 GCK IGF1
5 adipose tissue MP:0005375 10.13 ACE ADIPOQ IGF1 INS IRS1 LEP
6 immune system MP:0005387 10.13 CRP IAPP IGF1 INS IRS1 LEP
7 mortality/aging MP:0010768 9.97 IGF1 INS IRS1 LEP PPARG REN
8 liver/biliary system MP:0005370 9.96 ACE ADIPOQ ALB APOB GCK INS
9 muscle MP:0005369 9.65 ADIPOQ ALB APOB IGF1 INS IRS1
10 renal/urinary system MP:0005367 9.32 REN SLC5A2 ACE ADIPOQ ALB GCK

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53608-75-6
2
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
3
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
4
Glipizide Approved Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
5
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
6
Insulin Detemir Approved Phase 4,Phase 3,Phase 1 169148-63-4 5311023
7
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
8
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
9
Gliclazide Approved Phase 4,Phase 3,Phase 2 21187-98-4 3475
10
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10238-21-8 3488
11
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 274901-16-5 6918537
12
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 160337-95-1
13
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 133107-64-9
14
Nateglinide Approved, Investigational Phase 4,Phase 3,Phase 2 105816-04-4 60026
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 204656-20-2
17
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 103-90-2 1983
18
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
19
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
20
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135062-02-1 65981
21
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
22
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
23
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
24
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
25
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
26
Cilostazol Approved Phase 4 73963-72-1 2754
27
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
28
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
29
Orlistat Approved, Investigational Phase 4,Phase 2,Phase 1 96829-58-2 3034010
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
32
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
33
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 141758-74-9 15991534
34
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
35
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
36
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
37
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
38
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
39
Enalaprilat Approved Phase 4 76420-72-9 6917719
40
Adalimumab Approved Phase 4 331731-18-1 16219006
41
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
42
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
43
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
44
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
45
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
46 Parecoxib Approved Phase 4 198470-84-7
47
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
48
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
49
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
50
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142387-99-3, 95635-55-5 56959

Interventional clinical trials:

(show top 50) (show all 7952)
id Name Status NCT ID Phase
1 Lactate and Hypoglycemia Unknown status NCT01387477 Phase 4
2 Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas Unknown status NCT02003274 Phase 4
3 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
4 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
5 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4
6 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
7 The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes Unknown status NCT02248714 Phase 4
8 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4
9 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4
10 Multiple Grain in Type 2 Diabetes Unknown status NCT00337337 Phase 4
11 Variation in Sulphonylurea Response in Type 2 Diabetes Unknown status NCT00738088 Phase 4
12 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
13 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4
14 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4
15 Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Unknown status NCT00259168 Phase 4
16 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4
17 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
18 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
19 Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function Unknown status NCT01790308 Phase 4
20 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
21 The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones Unknown status NCT02180334 Phase 4
22 Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes Unknown status NCT01339143 Phase 4
23 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4
24 How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? Unknown status NCT00749047 Phase 4
25 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4
26 Triple Therapy in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4
27 Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study Unknown status NCT01417897 Phase 4
28 Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes Unknown status NCT00736515 Phase 4
29 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4
30 Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use Unknown status NCT01500850 Phase 4
31 Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation Unknown status NCT00936663 Phase 4
32 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4
33 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4
34 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4
35 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4
36 Korean AMADEUS Study Unknown status NCT01239849 Phase 4
37 Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin. Unknown status NCT00404599 Phase 4
38 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
39 Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy Unknown status NCT01565096 Phase 4
40 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4
41 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4
42 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4
43 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4
44 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Unknown status NCT01597531 Phase 4
45 The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients Unknown status NCT01510509 Phase 4
46 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4
47 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
48 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4
49 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4
50 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

Publications for Glucose Metabolism Disease

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 ADIPOQ GCK IAPP INS IRS1 LEP
2
Show member pathways
12.7 ADIPOQ INS IRS1 LEP SLC2A4
3 12.38 ADIPOQ GCG INS IRS1 PPARG SLC2A4
4
Show member pathways
12.32 ALB GCG GCK GIP INS
5
Show member pathways
12.28 ADIPOQ IGF1 INS IRS1 LEP PPARG
6
Show member pathways
12.23 ALB APOB CRP INS
7
Show member pathways
12.13 INS IRS1 LEP SLC2A4
8
Show member pathways
12.03 ADIPOQ IGF1 INS IRS1 PPARG
9
Show member pathways
11.99 IGF1 INS IRS1 SLC2A4
10 11.82 ADIPOQ IGF1 INS IRS1 LEP PPARG
11
Show member pathways
11.81 GCK SLC2A4 SLC5A2 SLC5A4
12
Show member pathways
11.79 GCK IAPP INS
13
Show member pathways
11.78 ADIPOQ GCK INS IRS1 SLC2A4
14 11.72 ADIPOQ IGF1 INS LEP PPARG SLC2A4
15 11.62 ADIPOQ IRS1 LEP SLC2A4
16
Show member pathways
11.49 ACE DPP4 GCG GIP IGF1 INS
17 11.48 IRS1 LEP SLC2A4
18
Show member pathways
11.48 DPP4 GCG GIP LEP
19 11.45 INS IRS1 LEP
20
Show member pathways
11.41 APOB GCG INS
21 11.38 ALB GCK INS
22 11.28 IGF1 INS IRS1
23 11.07 ADIPOQ LEP PPARG
24 10.7 ADIPOQ IRS1 LEP PPARG SLC2A4

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ACE ADIPOQ ALB APOB CRP DPP4
2 endoplasmic reticulum lumen GO:0005788 9.55 ALB APOB GCG GIP INS
3 extracellular space GO:0005615 9.44 ACE ADIPOQ ALB APOB CRP GCG

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 37)
id Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.93 GCK INS SLC2A4 SLC5A2
2 cellular protein metabolic process GO:0044267 9.91 ALB APOB IAPP IGF1 INS
3 response to organic substance GO:0010033 9.84 APOB PPARG REN
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.82 ADIPOQ IGF1 INS
5 positive regulation of MAPK cascade GO:0043410 9.82 IGF1 INS LEP
6 response to nutrient GO:0007584 9.8 ADIPOQ LEP PPARG
7 regulation of blood pressure GO:0008217 9.78 ACE LEP PPARG REN
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 IGF1 INS LEP
9 glucose metabolic process GO:0006006 9.76 ADIPOQ GCK INS LEP
10 response to nutrient levels GO:0031667 9.75 ADIPOQ GIP LEP
11 carbohydrate transport GO:0008643 9.72 SLC2A4 SLC5A2 SLC5A4
12 glucose transport GO:0015758 9.71 GCK INS SLC2A4
13 response to lipid GO:0033993 9.67 GIP PPARG
14 fatty acid oxidation GO:0019395 9.67 ADIPOQ PPARG
15 lipoprotein transport GO:0042953 9.67 APOB PPARG
16 glucose transmembrane transport GO:1904659 9.67 SLC2A4 SLC5A2 SLC5A4
17 positive regulation of glycolytic process GO:0045821 9.66 IGF1 INS
18 beta-amyloid metabolic process GO:0050435 9.65 ACE REN
19 insulin-like growth factor receptor signaling pathway GO:0048009 9.65 IGF1 IRS1
20 cellular response to insulin stimulus GO:0032869 9.65 ADIPOQ GCK IRS1 PPARG SLC2A4
21 angiotensin maturation GO:0002003 9.63 ACE REN
22 response to carbohydrate GO:0009743 9.62 APOB GIP
23 positive regulation of glucose import GO:0046326 9.62 ADIPOQ IGF1 INS IRS1
24 cellular response to leptin stimulus GO:0044320 9.61 GCK LEP
25 negative regulation of lipid storage GO:0010888 9.61 CRP LEP
26 negative regulation of gluconeogenesis GO:0045721 9.61 ADIPOQ GCK INS
27 response to selenium ion GO:0010269 9.6 APOB GIP
28 negative regulation of acute inflammatory response GO:0002674 9.58 INS PPARG
29 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.58 ADIPOQ CRP PPARG
30 negative regulation of vasodilation GO:0045908 9.57 CRP INS
31 bone mineralization involved in bone maturation GO:0035630 9.56 IGF1 LEP
32 regulation of insulin secretion GO:0050796 9.55 DPP4 GCG GCK GIP LEP
33 positive regulation of insulin receptor signaling pathway GO:0046628 9.54 INS IRS1 LEP
34 cellular response to prostaglandin stimulus GO:0071379 9.52 APOB PPARG
35 positive regulation of glycogen biosynthetic process GO:0045725 9.26 GCK IGF1 INS IRS1
36 glucose homeostasis GO:0042593 9.17 ADIPOQ GCK INS IRS1 LEP PPARG
37 positive regulation of cell proliferation GO:0008284 10.04 DPP4 IGF1 INS IRS1 LEP

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 ADIPOQ ALB DPP4 GCG IAPP INS
2 receptor binding GO:0005102 9.63 ADIPOQ DPP4 GCG IAPP LEP REN
3 drug binding GO:0008144 9.58 ACE ALB PPARG
4 insulin receptor binding GO:0005158 9.43 IGF1 INS IRS1
5 glucose:sodium symporter activity GO:0005412 9.37 SLC5A2 SLC5A4
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS IRS1 REN
7 hormone activity GO:0005179 9.17 ADIPOQ GCG GIP IAPP IGF1 INS

Sources for Glucose Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....